Tonga

Medicines oversight in Tonga is administered by the Ministry of Health and the National Drugs and Medical Supplies Committee under the national therapeutic-goods framework. The official guidelines for importing vaccines, medicines and medical devices explain that the Therapeutic Goods Act establishes the national committee and requires control of medical products entering the country. Suspected adverse reactions and product-quality concerns should be communicated to the Ministry of Health and handled through the national clinical and pharmacy channels. The reviewed public official documents do not establish a separate local QPPV or safety-contact requirement, PSMF, fixed expedited post-marketing ICSR timelines, a routine PSUR/PBRER schedule, mandatory RMP format or dedicated pharmacovigilance-inspection programme. Companies should maintain their global pharmacovigilance procedures, retain complete local safety records and confirm any product-specific reporting or risk-management obligations with the Ministry before supply. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.